Engrail’s precision psychiatry drugs get more buy in from venture investors
19 Mar 2024
IPO
Engrail Therapeutics, a San Diego-based biotechnology company, has raised another $157 million to support its work developing precision medicines for psychiatric conditions and rare disorders.
The fresh funds announced Tuesday come from a Series B financing round that received more interest than Engrail had expected. New investors F-Prime Capital, Forbion and Norwest Venture Partners co-led the round, which also saw participation from more than half a dozen other life sciences investors.
Engrail’s research revolves around modifying the neurotransmitters dopamine and GABA as well as cellular copper levels. The company’s most advanced drug, named ENX-102, is in human testing as a potential treatment for generalized anxiety disorder. It also has preclinical programs targeting depression, post-traumatic stress disorder and an uncommon, inherited illness known as Menkes disease.
“We see tremendous potential in Engrail’s pipeline and management team,” said Stacie Weninger, president of F-Prime Biomedical Research Initiative, which provides seed funding and guidance to startups advancing treatments for Alzheimer’s disease and related brain disorders.
Weninger and Jasper Bos, a general partner at Forbion, are now part of Engrail’s board of directors. The company has also added Tiba Aynechi, a general partner at Norwest Venture Partners; Niall O’Donnell, a managing director at RiverVest Venture Partners; and Heath Lukatch, a co-founder and managing partner at Red Tree Venture Capital.
A year after its establishment in 2019, Engrail raised $32 million through a Series A financing round led by Nan Fung Life Sciences, the global investment platform of the Nan Fung Group.
With its latest haul, Engrail joins a handful of other brain-focused biotechs that over the last year have brought in tens of millions of dollars for their research.
In early February, Alto Neuroscience, a company trying to create new treatments for central nervous system disorders, raked in nearly $130 million through an initial public offering. A week later, Neurona Therapeutics raised another $120 million to continue its work on “off-the-shelf” cell therapies for brain diseases. And most recently, Latigo Biotherapeutics debuted with $135 million to develop non-opioid pain medicines.
Last year, the biotechs Rapport Therapeutics, MapLight Therapeutics, VectorY Therapeutics and Nido Biosciences collectively raised more than $620 million through financing rounds of various stages. Richly-funded Neumora Therapeutics also grew its cash pile with an IPO that fetched $250 million.
'
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.